JP2016185988A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016185988A5 JP2016185988A5 JP2016145286A JP2016145286A JP2016185988A5 JP 2016185988 A5 JP2016185988 A5 JP 2016185988A5 JP 2016145286 A JP2016145286 A JP 2016145286A JP 2016145286 A JP2016145286 A JP 2016145286A JP 2016185988 A5 JP2016185988 A5 JP 2016185988A5
- Authority
- JP
- Japan
- Prior art keywords
- cell culture
- vaccine
- dna
- residual
- bpl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004113 cell culture Methods 0.000 claims 15
- 229960005486 vaccine Drugs 0.000 claims 13
- 238000000034 method Methods 0.000 claims 10
- 238000009472 formulation Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical group O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 4
- 229940100198 alkylating agent Drugs 0.000 claims 4
- 239000002168 alkylating agent Substances 0.000 claims 4
- 229960000380 propiolactone Drugs 0.000 claims 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 2
- 239000007764 o/w emulsion Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229940031439 squalene Drugs 0.000 claims 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 2
- 210000002845 virion Anatomy 0.000 claims 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 238000001818 capillary gel electrophoresis Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 1
- 230000000593 degrading effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 210000003501 vero cell Anatomy 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73278605P | 2005-11-01 | 2005-11-01 | |
| US60/732,786 | 2005-11-01 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014149517A Division JP6639077B2 (ja) | 2005-11-01 | 2014-07-23 | β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016185988A JP2016185988A (ja) | 2016-10-27 |
| JP2016185988A5 true JP2016185988A5 (enExample) | 2017-01-05 |
| JP7049761B2 JP7049761B2 (ja) | 2022-04-07 |
Family
ID=37969762
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008538454A Active JP5602366B2 (ja) | 2005-11-01 | 2006-11-01 | β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
| JP2011206634A Withdrawn JP2011256209A (ja) | 2005-11-01 | 2011-09-21 | β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
| JP2014149517A Active JP6639077B2 (ja) | 2005-11-01 | 2014-07-23 | β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
| JP2016145286A Active JP7049761B2 (ja) | 2005-11-01 | 2016-07-25 | β－プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
| JP2019192740A Pending JP2020023557A (ja) | 2005-11-01 | 2019-10-23 | β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008538454A Active JP5602366B2 (ja) | 2005-11-01 | 2006-11-01 | β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
| JP2011206634A Withdrawn JP2011256209A (ja) | 2005-11-01 | 2011-09-21 | β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
| JP2014149517A Active JP6639077B2 (ja) | 2005-11-01 | 2014-07-23 | β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019192740A Pending JP2020023557A (ja) | 2005-11-01 | 2019-10-23 | β−プロピオラクトン処理による低レベルの残存細胞ＤＮＡを含む細胞由来のウイルスワクチン |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10655108B2 (enExample) |
| EP (3) | EP2842572A1 (enExample) |
| JP (5) | JP5602366B2 (enExample) |
| KR (1) | KR20080081254A (enExample) |
| CN (2) | CN104474543A (enExample) |
| AT (1) | ATE494906T1 (enExample) |
| AU (2) | AU2006310171B2 (enExample) |
| CA (1) | CA2627971A1 (enExample) |
| CY (1) | CY1111378T1 (enExample) |
| DE (1) | DE602006019629D1 (enExample) |
| DK (1) | DK1951296T4 (enExample) |
| EA (1) | EA014062B1 (enExample) |
| ES (2) | ES2525518T3 (enExample) |
| HK (1) | HK1207828A1 (enExample) |
| NZ (1) | NZ567817A (enExample) |
| PL (2) | PL2301572T3 (enExample) |
| PT (1) | PT2301572E (enExample) |
| SI (1) | SI1951296T2 (enExample) |
| WO (1) | WO2007052163A2 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE494906T1 (de) * | 2005-11-01 | 2011-01-15 | Novartis Vaccines & Diagnostic | Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna |
| PL2478916T3 (pl) | 2006-01-27 | 2020-11-16 | Seqirus UK Limited | Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy |
| NZ575271A (en) | 2006-09-11 | 2011-09-30 | Novartis Ag | Making influenza virus vaccines without using eggs |
| PT2185191E (pt) | 2007-06-27 | 2012-11-27 | Novartis Ag | Vacinas contra a gripe com baixo teor de aditivos |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| JP5518041B2 (ja) | 2008-03-18 | 2014-06-11 | ノバルティス アーゲー | インフルエンザウイルスワクチン抗原の調製における改良 |
| EP2361304A2 (en) | 2008-11-05 | 2011-08-31 | GlaxoSmithKline Biologicals S.A. | Novel method |
| DE102010018462A1 (de) | 2009-04-27 | 2011-04-07 | Novartis Ag | Impfstoffe zum Schutz gegen Influenza |
| JP5836266B2 (ja) | 2009-05-21 | 2015-12-24 | ノバルティス アーゲー | 非内因性ｐｏｌＩプロモーターを使用した逆遺伝学 |
| WO2011012999A1 (en) | 2009-07-31 | 2011-02-03 | Novartis Ag | Reverse genetics systems |
| WO2011044576A2 (en) | 2009-10-09 | 2011-04-14 | Children's Medical Center Corporation | Selectively disrupted whole-cell vaccine |
| KR20120083480A (ko) | 2009-10-20 | 2012-07-25 | 노파르티스 아게 | 바이러스 구제를 위한 개선된 역유전학 방법 |
| EP2566958B1 (en) | 2010-05-03 | 2015-12-30 | GlaxoSmithKline Biologicals S.A. | Method for inactivating influenza virus |
| JP6072677B2 (ja) * | 2010-05-06 | 2017-02-01 | ノバルティス アーゲー | 微生物の不活化のための有機ペルオキシド化合物 |
| JP5876036B2 (ja) | 2010-05-21 | 2016-03-02 | ノバルティス アーゲー | インフルエンザウイルス再集合方法 |
| PL2575872T3 (pl) | 2010-06-01 | 2021-02-22 | Seqirus UK Limited | Zatężanie antygenów szczepionkowych grypy bez liofilizacji |
| CA2801151A1 (en) | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens with lyophilization |
| EP2603234B1 (en) | 2010-08-12 | 2017-06-28 | Yisheng Biopharma Holdings Ltd. | Method for reducing dna impurities in viral compositions |
| CA2808965C (en) | 2010-08-20 | 2020-01-07 | Theraject, Inc. | Soluble needle arrays for delivery of influenza vaccines |
| US9580761B2 (en) | 2011-02-25 | 2017-02-28 | Novartis Ag | Exogenous internal positive control |
| AU2012360168C1 (en) | 2011-11-03 | 2017-09-28 | Sentinext Therapeutics Sdn Bhd | Vaccines directed against human Enteroviruses |
| GB2495341B (en) | 2011-11-11 | 2013-09-18 | Novartis Ag | Fermentation methods and their products |
| WO2013087945A2 (en) | 2012-03-02 | 2013-06-20 | Novartis Ag | Influenza virus reassortment |
| CN104159608A (zh) | 2012-03-06 | 2014-11-19 | 克鲁塞尔荷兰公司 | 针对流感的改善的疫苗接种 |
| WO2013182498A1 (en) | 2012-06-04 | 2013-12-12 | Novartis Ag | Improved safety testing |
| US9708585B2 (en) | 2012-12-03 | 2017-07-18 | Seqirus UK Limited | Influenza virus reassortment |
| CA2905612A1 (en) | 2013-03-13 | 2014-09-18 | Novartis Ag | Influenza virus reassortment |
| JP2016521282A (ja) | 2013-05-10 | 2016-07-21 | ノバルティス アーゲー | インフルエンザワクチンにおけるナルコレプシーのリスクの回避 |
| DE202013005100U1 (de) | 2013-06-05 | 2013-08-26 | Novartis Ag | Influenza Virus Reassortierung |
| DE202013005130U1 (de) | 2013-06-05 | 2013-09-10 | Novartis Ag | Influenza Virus Reassortierung |
| CN105722976A (zh) | 2013-06-06 | 2016-06-29 | 诺华股份有限公司 | 流感病毒重配 |
| CN104436157A (zh) | 2013-09-23 | 2015-03-25 | 恩金生物有限公司 | 流感疫苗和治疗 |
| US10080792B2 (en) | 2013-09-23 | 2018-09-25 | Engen Bio, Inc. | Influenza vaccine and therapy |
| CN104513317B (zh) * | 2013-09-30 | 2018-12-14 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其制备方法和应用 |
| CA2930634C (en) | 2013-11-15 | 2023-05-09 | Novartis Ag | Removal of influenza nuclear protein (np) from influenza virus preparations |
| JP6774149B2 (ja) * | 2014-05-28 | 2020-10-21 | ナショナル ヘルス リサーチ インスティテューツＮａｔｉｏｎａｌ Ｈｅａｌｔｈ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅｓ | エンテロウイルス感染に対する免疫原としてのウイルス粒子およびその生産 |
| KR20180035807A (ko) | 2015-06-26 | 2018-04-06 | 세퀴러스 유케이 리미티드 | 항원적으로 매치된 인플루엔자 백신 |
| AU2016290603B2 (en) | 2015-07-07 | 2022-06-02 | Seqirus UK Limited | Influenza potency assays |
| EP3184119A1 (en) * | 2015-12-23 | 2017-06-28 | Themis Bioscience GmbH | Chromatography based purification strategies for measles scaffold based viruses |
| WO2019086463A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| CN109652384B (zh) * | 2019-02-21 | 2021-10-26 | 昆明理工大学 | 一种体外培养戊型肝炎病毒的方法 |
| EP4054630A2 (en) * | 2019-11-07 | 2022-09-14 | Seqirus UK Limited | Compositions and methods for producing a viral vaccine with reduced particle size |
| EP4061930A1 (en) | 2019-11-18 | 2022-09-28 | Seqirus Pty Ltd | Method for producing reassortant influenza viruses |
| KR20230157397A (ko) * | 2021-03-30 | 2023-11-16 | 덴카 주식회사 | 인플루엔자 백신 |
| CN116064426A (zh) * | 2022-07-05 | 2023-05-05 | 非凡生命科学技术(昆山)有限公司 | 一种灭活bk病毒及其用途 |
| CN115354071A (zh) * | 2022-08-10 | 2022-11-18 | 上海药明生基医药科技有限公司 | 一种检测重组腺相关病毒宿主细胞dna残留的方法 |
| CN116407624B (zh) * | 2023-04-14 | 2024-04-09 | 吉林省农业科学院(中国农业科技东北创新中心) | 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用 |
| TW202516000A (zh) * | 2023-07-25 | 2025-04-16 | 日商Ｋｍ生物醫藥股份有限公司 | 利用雞蛋培養法進行的去活化流感疫苗的製備方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4140762A (en) * | 1974-01-14 | 1979-02-20 | Sandoz Ltd. | Influenza sub-unit vaccine |
| CH589453A5 (enExample) * | 1974-01-14 | 1977-07-15 | Sandoz Ag | |
| US4064232A (en) * | 1974-01-14 | 1977-12-20 | Sandoz Ltd. | Process for isolating the immunogenic components of influenza viruses |
| JP2661044B2 (ja) | 1986-06-17 | 1997-10-08 | カイロン コーポレイション | 肝炎δの診断薬およびワクチン |
| GB8703696D0 (en) * | 1987-02-18 | 1987-03-25 | Oxford J S | Influenza vaccine |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5010183A (en) | 1989-07-07 | 1991-04-23 | Macfarlane Donald E | Process for purifying DNA and RNA using cationic detergents |
| JP2941859B2 (ja) | 1989-09-20 | 1999-08-30 | 国立予防衛生研究所 | Ｈａ蛋白の製造法 |
| US5010112A (en) * | 1989-12-01 | 1991-04-23 | Massachusetts Institute Of Technology | Method and apparatus for improving the insulating properties of closed cell foam |
| US5824536A (en) | 1994-08-23 | 1998-10-20 | St. Jude Children's Research Hospital | Influenza virus replicated in mammalian cell culture and vaccine production |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| DE19612966B4 (de) * | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| WO1999062546A1 (en) * | 1998-06-01 | 1999-12-09 | Chiron Corporation | Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants |
| JP2000230931A (ja) | 1998-12-07 | 2000-08-22 | Katakura Industries Co Ltd | 家畜インフルエンザウイルスに対する抗体の検出方法およびこれに用いるキット |
| DK1187629T3 (da) * | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| PL355287A1 (en) | 1999-09-24 | 2004-04-05 | Smithkline Beecham Biologicals S.A. | Intranasal influenza virus vaccine |
| EP1103610A1 (en) | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
| CA2393469A1 (en) | 1999-12-08 | 2001-06-14 | Crucell Holland B.V. | Method of administering adenovirus |
| CA2401117C (en) | 2000-03-03 | 2010-06-29 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell |
| FR2808803B1 (fr) | 2000-05-11 | 2004-12-10 | Agronomique Inst Nat Rech | Cellules es modifiees et gene specifique de cellules es |
| GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
| EP1361890B1 (en) | 2001-02-23 | 2011-03-30 | GlaxoSmithKline Biologicals s.a. | Influenza vaccine formulations for intradermal delivery |
| WO2002067983A1 (en) | 2001-02-23 | 2002-09-06 | Glaxosmithkline Biologicals S.A. | Novel vaccine |
| CA2445120A1 (en) | 2001-04-27 | 2002-11-07 | Glaxosmithkline Biologicals Sa | Devices for the intradermal administration of influenza vaccines |
| MY134424A (en) | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
| US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
| DE10144903A1 (de) | 2001-09-12 | 2003-03-27 | Chiron Behring Gmbh & Co | Vermehrung von Viren in Zellkultur |
| DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| CN1678345B (zh) | 2002-04-26 | 2013-09-11 | 米迪缪尼有限公司 | 制备流感病毒的多质粒系统 |
| CA2501975A1 (en) | 2002-12-20 | 2004-07-08 | Crucell Holland B.V. | Recombinant virus production for the manufacturing of vaccines |
| US20060257852A1 (en) * | 2003-04-10 | 2006-11-16 | Chiron Corporation | Severe acute respiratory syndrome coronavirus |
| ES2593082T3 (es) | 2003-05-28 | 2016-12-05 | Wisconsin Alumni Research Foundation | Virus de la gripe recombinantes a título elevado para vacunas y terapia génica |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| CN1922308A (zh) | 2004-02-23 | 2007-02-28 | 克鲁塞尔荷兰公司 | 病毒纯化方法 |
| WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
| AU2005245943A1 (en) | 2004-05-20 | 2005-12-01 | Id Biomedical Corporation | Process for the production of an influenza vaccine |
| RS51665B (sr) * | 2004-09-09 | 2011-10-31 | Novartis Vaccines And Diagnostics Gmbh. | Smanjenje potencijalnih jatrogenih rizika povezanih sa vakcinama protiv gripa |
| JP4031478B2 (ja) | 2004-12-13 | 2008-01-09 | プロテイン サイエンシーズ | インフルエンザ血球凝集素多価ワクチンの製造方法 |
| ES2526170T3 (es) | 2004-12-23 | 2015-01-07 | Medimmune, Llc | Línea celular MDCK no tumorigénica para propagar virus |
| FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
| ATE494906T1 (de) * | 2005-11-01 | 2011-01-15 | Novartis Vaccines & Diagnostic | Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna |
| AU2007347716B2 (en) * | 2006-09-15 | 2013-06-20 | Medimmune, Llc | MDCK cell lines supporting viral growth to high titers and bioreactor process using the same |
-
2006
- 2006-11-01 AT AT06831855T patent/ATE494906T1/de active
- 2006-11-01 EP EP14183359.0A patent/EP2842572A1/en not_active Ceased
- 2006-11-01 US US12/092,190 patent/US10655108B2/en active Active
- 2006-11-01 EP EP10075529.7A patent/EP2301572B1/en not_active Revoked
- 2006-11-01 EP EP06831855.9A patent/EP1951296B2/en active Active
- 2006-11-01 PL PL10075529T patent/PL2301572T3/pl unknown
- 2006-11-01 AU AU2006310171A patent/AU2006310171B2/en active Active
- 2006-11-01 PL PL06831855T patent/PL1951296T5/pl unknown
- 2006-11-01 KR KR1020087013164A patent/KR20080081254A/ko not_active Ceased
- 2006-11-01 ES ES10075529.7T patent/ES2525518T3/es active Active
- 2006-11-01 DK DK06831855.9T patent/DK1951296T4/da active
- 2006-11-01 CA CA002627971A patent/CA2627971A1/en not_active Abandoned
- 2006-11-01 JP JP2008538454A patent/JP5602366B2/ja active Active
- 2006-11-01 NZ NZ567817A patent/NZ567817A/en not_active IP Right Cessation
- 2006-11-01 CN CN201410631136.2A patent/CN104474543A/zh active Pending
- 2006-11-01 SI SI200630957T patent/SI1951296T2/sl unknown
- 2006-11-01 EA EA200801221A patent/EA014062B1/ru not_active IP Right Cessation
- 2006-11-01 CN CN200680046034.8A patent/CN101365480B/zh not_active Expired - Fee Related
- 2006-11-01 ES ES06831855.9T patent/ES2359214T5/es active Active
- 2006-11-01 WO PCT/IB2006/003880 patent/WO2007052163A2/en not_active Ceased
- 2006-11-01 DE DE602006019629T patent/DE602006019629D1/de active Active
- 2006-11-01 PT PT100755297T patent/PT2301572E/pt unknown
-
2011
- 2011-04-05 CY CY20111100356T patent/CY1111378T1/el unknown
- 2011-04-29 AU AU2011201968A patent/AU2011201968B2/en active Active
- 2011-09-21 JP JP2011206634A patent/JP2011256209A/ja not_active Withdrawn
-
2014
- 2014-07-23 JP JP2014149517A patent/JP6639077B2/ja active Active
-
2015
- 2015-09-01 HK HK15108523.2A patent/HK1207828A1/en unknown
-
2016
- 2016-07-25 JP JP2016145286A patent/JP7049761B2/ja active Active
-
2019
- 2019-10-23 JP JP2019192740A patent/JP2020023557A/ja active Pending
-
2020
- 2020-04-09 US US16/843,940 patent/US11466257B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11739303B2 (en) | Recombinant influenza viruses with stabilized NA | |
| Rockman et al. | New technologies for influenza vaccines | |
| Wong et al. | Traditional and new influenza vaccines | |
| Crisci et al. | Virus-like particles: the new frontier of vaccines for animal viral infections | |
| JP2013537518A5 (enExample) | ||
| JP2014532620A5 (enExample) | ||
| EP2301572B1 (en) | Cell-derived viral vaccines with low levels of residual cell dna | |
| Alqazlan et al. | Strategies for enhancing immunity against avian influenza virus in chickens: A review | |
| Atmar et al. | Adjuvants for pandemic influenza vaccines | |
| JP6300827B2 (ja) | ケイ化ウイルスを含む免疫原性組成物および使用の方法 | |
| JP2016155867A5 (enExample) | ||
| JP2011504486A5 (enExample) | ||
| Yan et al. | Protection of chickens against infectious bronchitis virus with a multivalent DNA vaccine and boosting with an inactivated vaccine | |
| Even-Or et al. | Adjuvanted influenza vaccines | |
| US11123421B2 (en) | Cold adapted and virulence factor deleted live attenuated vaccine suitable for mucosal delivery | |
| Fawzy et al. | Nanoparticles as a novel and promising antiviral platform in veterinary medicine | |
| Mokalla et al. | Influenza vaccines: current status, adjuvant strategies, and efficacy | |
| B. Carvalho et al. | Downstream processing for influenza vaccines and candidates: An update | |
| Wang et al. | The potential adjuvanticity of quaternized chitosan hydrogel based microparticles for porcine reproductive and respiratory syndrome virus inactivated vaccine | |
| JP2019520090A (ja) | 弱毒変異型ジカウイルスを含むワクチン組成物 | |
| JP2025072575A (ja) | インフルエンザウイルスバックボーン | |
| JP7849046B2 (ja) | インフルエンザウイルスバックボーン | |
| CA2722558A1 (en) | Methods for preparing immunogenic compositions | |
| RU2599496C2 (ru) | Улучшенная вакцинация против гриппа | |
| WO2012058492A2 (en) | Viral vaccine and process for preparing the same |